LIFECORE BIOMEDICAL, INC. DE
LFCR evidence brief
What we can confirm
- Market Cap:
- $156.0M
What it means
What to watch
Prepared research question
What matters most for LFCR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LFCR
LIFECORE BIOMEDICAL, INC. DE (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in the cGMP manufacturing and aseptic filling of complex sterile injectable products, including pharmaceutical-grade hyaluronic acid.
Key risk: Negative equity and net loss
Market Cap
$156.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
LIFECORE BIOMEDICAL, INC. DE (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in the cGMP manufacturing and aseptic filling of complex sterile injectable products, including pharmaceutical-grade hyaluronic acid.
- Lifecore is a fully integrated CDMO offering clinical and commercial capabilities in development, cGMP manufacturing, and aseptic filling of complex formulations and highly viscous sterile injectable products [sec_mda · as of 2026-08-05].
- The company manufactures pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) in bulk form and for use in formulated and filled syringes and vials [sec_mda · as of 2026-08-05].
- As of 2026-06-30, Lifecore reported cash & equivalents of $17.2M, total revenue of $34.2M, net income of -$6.2M, and shareholders' equity of -$34.1M [sec].
- In January 2026, Lifecore implemented a new enterprise resource planning (ERP) system to enhance inventory control, data visibility, and financial management [sec_mda · as of 2026-08-05].
- The company strengthened its financial position through a $24.3M private placement in October 2024 and a three-year term extension of its asset-based lending credit facility in November 2024 [sec_mda · as of 2026-08-05].
What works
- Lifecore has a differentiated CDMO platform with capabilities in complex formulations and highly viscous sterile injectables, including pharmaceutical-grade HA manufacturing [sec_mda · as of 2026-08-05].
- The company has taken steps to strengthen its financial position, including a $24.3M private placement and a credit facility extension [sec_mda · as of 2026-08-05].
- Implementation of a new ERP system in January 2026 aims to improve operational efficiency and data management [sec_mda · as of 2026-08-05].
What to weigh
- Lifecore reported a net loss of -$6.2M and negative shareholders' equity of -$34.1M as of 2026-06-30 [sec].
- The company faces risks related to customer demand, regulatory compliance, and the need for additional financing [sec_mda · as of 2026-08-05].
- Forward-looking statements are subject to uncertainties that may cause actual results to differ materially from expectations [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
Lifecore is a fully integrated CDMO for complex sterile injectables.
“Lifecore is a fully integrated CDMO that offers highly differentiated clinical and commercial capabilities in the development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials and cartridges, across a wide variety of modalities.”
SEC MD&A · August 5, 2026
Lifecore manufactures pharmaceutical-grade hyaluronic acid.
“We manufacture pharmaceutical-grade, non-animal-sourced hyaluronic acid ("HA") in bulk form as well as for use in formulated and filled syringes and vials”
SEC MD&A · August 5, 2026
Lifecore implemented a new ERP system in January 2026.
“In January 2026, Lifecore implemented a new enterprise resource planning ("ERP") system designed to enhance inventory control, data visibility, and financial management.”
SEC MD&A · August 5, 2026
Catalyst timeline
- 2025-01-02 · Earnings Report - SEC 8-K filing — Routine quarterly earnings filing providing updated financial results.
- 2025-04-03 · Earnings Report - SEC 8-K filing — Routine quarterly earnings filing providing updated financial results.
- 2025-08-07 · Earnings Report - SEC 8-K filing — Routine quarterly earnings filing providing updated financial results.
- 2025-11-06 · Earnings Report - SEC 8-K filing — Routine quarterly earnings filing providing updated financial results.
- 2026-03-16 · Earnings Report - SEC 8-K filing — Routine quarterly earnings filing providing updated financial results.
- 2026-05-06 · Earnings Report - SEC 8-K filing — Routine quarterly earnings filing providing updated financial results.
- 2026-08-05 · Earnings Report - SEC 8-K filing — Routine quarterly earnings filing providing updated financial results.
Risks & what to watch (3)›
Key risks
- Negative equity and net loss — Shareholders' equity of -$34.1M and net loss of -$6.2M as of 2026-06-30 indicate financial strain [sec].
- Dependence on customer demand — Revenue and growth depend on maintaining and expanding customer relationships, which may be affected by market changes [sec_mda · as of 2026-08-05].
- Regulatory and compliance risks — The company must comply with stringent U.S. and foreign regulations, including cGMP, which may impact operations [sec · filed 2026-07-02].
What to watch
- Future earnings reports and financial filings to track progress on net income and equity [catalyst].
- Customer and revenue growth following the ERP implementation and strategic initiatives [sec_mda · as of 2026-08-05].
- Any additional financing or capital requirements as the company executes its strategic plan [sec_mda · as of 2026-08-05].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run LIFECORE BIOMEDICAL, INC. DE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LIFECORE BIOMEDICAL, INC. DE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of Apr 30, 2026- % of float
- 12.4%
- Days to cover
- 4.3
- Shares short
- 2,651,650
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LFCR short interestGovernance
Frequently asked questions
What is the AI investment thesis for LIFECORE BIOMEDICAL, INC. DE?
LIFECORE BIOMEDICAL, INC. DE (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in the cGMP manufacturing and aseptic filling of complex sterile injectable products, including pharmaceutical-grade hyaluronic acid.
Who is the CEO of LIFECORE BIOMEDICAL, INC. DE?
Mr. Paul Josephs is the chief executive officer of LIFECORE BIOMEDICAL, INC. DE (LFCR).
Where is LIFECORE BIOMEDICAL, INC. DE headquartered?
LIFECORE BIOMEDICAL, INC. DE (LFCR) is headquartered in Chaska, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.